SCHEMBL14922320

SCHEMBL14922320

CC(C)COc1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.52
KDM4E B2RXH2 2/20 0.50
GLA P06280 2/20 0.50
MELK Q14680 1/20 0.49
KMT2A Q03164 6/20 0.49
MEN1 O00255 5/20 0.49
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
POLB P06746 1/20 0.49
HRH4 Q9H3N8 1/20 0.49
MAPT P10636 5/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
ADRA2C P18825 1/20 0.49
GFER P55789 1/20 0.49
PTK2B Q14289 1/20 0.49
ESR2 Q92731 1/20 0.49
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21659260 0.87 KDM4E (0.55) HRH3KDM4EGLAKMT2AMEN1
SCHEMBL14922745 0.86 KMT2A (0.49) HRH3KDM4EGLAKMT2AMEN1
SCHEMBL14922322 0.86 ITGB3 (0.52) HRH3KDM4EGLAKMT2AMEN1
SCHEMBL18210667 0.83 MAPT (0.46) KMT2AMEN1ITGB3ITGA2BMAPT
SCHEMBL9984913 0.82 ADRB1 (0.60) KMT2AMEN1ITGB3ITGA2BHRH4
SCHEMBL8363117 0.81 KMT2A (0.66) HRH3KDM4EGLAKMT2AMEN1
SCHEMBL28977192 0.81 MELK (0.66) HRH3MELKMAPTGAA
Hydrochloric Acid SCHEMBL382274 0.81 ADRB1 (0.58) KMT2AMEN1ITGB3ITGA2BHRH4
SCHEMBL14922746 0.80 HRH3 (0.50) HRH3KDM4EGLAKMT2AMEN1
SCHEMBL12041607 0.80 KMT2A (0.54) KDM4EKMT2AMEN1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210054017-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE IONIS PHARMACEUTICALS INC (US) 2021-02-25 US disclosed
US-10570169-B2 Conjugated antisense compounds and their use IONIS PHARMACEUTICALS, INC. (US) 2020-02-25 US disclosed
US-20170355727-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE IONIS PHARMACEUTICALS, INC. (US) 2017-12-14 US disclosed
US-20170355727-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE IONIS PHARMACEUTICALS, INC. (US) 2017-12-14 US disclosed
US-20170145424-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2017-05-25 US disclosed
US-20170145424-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS IONIS PHARMACEUTICALS, INC. (US) 2017-05-25 US disclosed
US-9486422-B2 Small molecule inhibitors of Mcl-1 and the uses of thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-11-08 US disclosed
US-RE44205-E1 Adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210054017-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE GNE, FUT6, GALNT13 HRH3 4844/4885KDM4E 3550/4885GLA 84/4885
US-10570169-B2 Conjugated antisense compounds and their use GNE, GALNT1, GALNT6 HRH3 4843/4885KDM4E 3756/4885GLA 135/4885
US-20170145424-A1 COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS SI, FABP2, GNE HRH3 4431/4885KDM4E 4014/4885GLA 95/4885
US-20170355727-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE GNE, GALNT1, GALNT6 HRH3 4843/4885KDM4E 3756/4885GLA 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.